MISSISSAUGA, Ontario, April 11, 2007 (PRIME NEWSWIRE) -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article by Greg Moses, an AllPennyStocks.com News Reporter, this one discussing Oramed Pharmaceuticals, Inc. (OTCBB:ORMP), its industry and future prospects.
With Diabetes as a rapidly growing disease worldwide impacting 200 million people, the search for advanced treatment solutions is center stage. Several firms are in the competitive race to replace the need for insulin injection therapy. One such alternative approach is the oral insulin product, under development from Oramed Pharmaceuticals, Inc.
Oral insulin alternatives may have huge potential benefits for millions of Type II Diabetics in the later stage of the disease. Oramed is currently developing an orally ingestible soft gel insulin capsule for the treatment of both types 1 and 2 diabetes. Until recently, the idea of an orally administered insulin therapy was inconceivable due to gastric degradation in the digestive system. Oramed has been successful in engineering around that challenge.
The full version of this special report on ORMP can be found at:
http://www.allpennystocks.com/aps_us/special_reports/archives/041007.asp
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and U.S. site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly stocks to watch, has a weekly market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTC BB, and much more information for the average investor.
Although the majority of AllPennyStocks.com reports are independent, it has received compensation for carrying the report on Oramed Pharmaceuticals, Inc. (OTCBB:ORMP), the compensation is three thousand dollars from a non-affiliated third-party, BlueWave Advisors for its efforts in presenting the ORMP profile on its web site and distributing it to its database of subscribers as well as other services. This creates an inherent conflict of interest and readers are encouraged to view the main disclaimer at http://www.allpennystocks.com/aps_us/company_spotlights/archives/ormp.asp.